TY - JOUR
T1 - Outcomes of Chronic Thromboembolic Pulmonary Hypertension After Balloon Pulmonary Angioplasty and Pulmonary Endarterectomy
AU - the CTEPH AC Registry Study Group
AU - Masaki, Kohei
AU - Hosokawa, Kazuya
AU - Funakoshi, Kouta
AU - Taniguchi, Yu
AU - Adachi, Shiro
AU - Inami, Takumi
AU - Yamashita, Jun
AU - Ogino, Hitoshi
AU - Tsujino, Ichizo
AU - Hatano, Masaru
AU - Yaoita, Nobuhiro
AU - Ikeda, Nobutaka
AU - Shimokawahara, Hiroto
AU - Tanabe, Nobuhiro
AU - Kubota, Kayoko
AU - Shigeta, Ayako
AU - Ogihara, Yoshito
AU - Horimoto, Koshin
AU - Dohi, Yoshihiro
AU - Kawakami, Takashi
AU - Tamura, Yuichi
AU - Tatsumi, Koichiro
AU - Abe, Kohtaro
AU - Hiraide, Takahiro
AU - Ikemiyagi, Hidekazu
AU - Fukumoto, Yoshihiro
AU - Ikeda, Satoshi
AU - Sato, Kimi
AU - Kimura, Kazuhiro
AU - Sugimoto, Koichi
AU - Kitaoka, Hiroaki
AU - Tsujita, Kenichi
AU - Sato, Akira
AU - Sugimura, Koichiro
AU - Takamura, Masayuki
AU - Hashimoto, Akiyoshi
AU - Konishi, Hakuoh
AU - Odagiri, Keiichi
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/8
Y1 - 2024/8
N2 - Background: The contemporary outcome of balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) are unclear. Objectives: This study aimed to clarify the characteristics and outcomes of CTEPH patients treated with BPA and PEA in Japan. Methods: Among 1,270 participants enrolled between 2018 and 2023 in the CTEPH AC (Chronic Thromboembolic Pulmonary Hypertension Anticoagulant) registry, a Japanese nationwide CTEPH registry, 369 treatment-naive patients (BPA strategy: n = 313; PEA strategy: n = 56) and 690 on-treatment patients (BPA strategy: n = 561; PEA strategy: n = 129) were classified according to the presence of prior reperfusion therapy. Morbidity and mortality events (all-cause death, rescue mechanical reperfusion therapy, and/or initiation of parenteral pulmonary vasodilators), pulmonary hemodynamics, exercise tolerance, and relevant laboratory test results were evaluated. Results: The BPA strategy was chosen in older patients than the PEA strategy (mean age, BPA vs PEA: 66.5 ± 12.6 years vs 62.5 ± 11.8 years; P = 0.028). Median follow-up period was 615 (Q1-Q3: 311-997) days in treatment-naive patients and 1,136 (Q1-Q3: 684-1,300) days in on-treatment patients. BPA strategy had as acceptable morbidity and mortality as PEA strategy (5-year morbidity and mortality event rate, BPA vs PEA: 10.2% [95% CI: 5.2%-19.5%] vs 16.1% [95% CI: 4.3%-50.6%] in treatment-naive patients; 9.7% [95% CI: 6.7%-13.8%] vs 6.9% [95% CI: 2.7%-17.3%] in on-treatment patients), with greater improvement of renal function; glomerular filtration rate in propensity score-matched population (difference between change: 4.9 [95% CI: 0.5-9.3] mL/min/1.73 m2; P = 0.030). Conclusions: BPA strategy was more frequently chosen in older patients compared with PEA strategy and showed acceptable outcomes for efficacy with greater advantage for improvement in renal function.
AB - Background: The contemporary outcome of balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) are unclear. Objectives: This study aimed to clarify the characteristics and outcomes of CTEPH patients treated with BPA and PEA in Japan. Methods: Among 1,270 participants enrolled between 2018 and 2023 in the CTEPH AC (Chronic Thromboembolic Pulmonary Hypertension Anticoagulant) registry, a Japanese nationwide CTEPH registry, 369 treatment-naive patients (BPA strategy: n = 313; PEA strategy: n = 56) and 690 on-treatment patients (BPA strategy: n = 561; PEA strategy: n = 129) were classified according to the presence of prior reperfusion therapy. Morbidity and mortality events (all-cause death, rescue mechanical reperfusion therapy, and/or initiation of parenteral pulmonary vasodilators), pulmonary hemodynamics, exercise tolerance, and relevant laboratory test results were evaluated. Results: The BPA strategy was chosen in older patients than the PEA strategy (mean age, BPA vs PEA: 66.5 ± 12.6 years vs 62.5 ± 11.8 years; P = 0.028). Median follow-up period was 615 (Q1-Q3: 311-997) days in treatment-naive patients and 1,136 (Q1-Q3: 684-1,300) days in on-treatment patients. BPA strategy had as acceptable morbidity and mortality as PEA strategy (5-year morbidity and mortality event rate, BPA vs PEA: 10.2% [95% CI: 5.2%-19.5%] vs 16.1% [95% CI: 4.3%-50.6%] in treatment-naive patients; 9.7% [95% CI: 6.7%-13.8%] vs 6.9% [95% CI: 2.7%-17.3%] in on-treatment patients), with greater improvement of renal function; glomerular filtration rate in propensity score-matched population (difference between change: 4.9 [95% CI: 0.5-9.3] mL/min/1.73 m2; P = 0.030). Conclusions: BPA strategy was more frequently chosen in older patients compared with PEA strategy and showed acceptable outcomes for efficacy with greater advantage for improvement in renal function.
KW - pulmonary embolism
KW - pulmonary hypertension
KW - registry
KW - thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=85199700661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85199700661&partnerID=8YFLogxK
U2 - 10.1016/j.jacasi.2024.05.007
DO - 10.1016/j.jacasi.2024.05.007
M3 - Article
AN - SCOPUS:85199700661
SN - 2772-3747
VL - 4
SP - 577
EP - 589
JO - JACC: Asia
JF - JACC: Asia
IS - 8
ER -